AbbVie Maintains Xeljanz Safety Concerns Don’t Spill Over To Rinvoq

 
• By Joseph Haas

Responding to Pfizer post-marketing data indicating risk for CV events or cancer in patients taking Xeljanz, AbbVie tells Q4 earnings call that a more selective JAK inhibitor like Rinvoq will offer better safety.

4th quarter computer key on key board
AbbVie's Q4 revenues came in strong despite some pandemic impact on the cancer franchise

More from Earnings

More from Business